Research outlook

Where bronchiectasis treatment is heading

Bronchiectasis · Updated Nov 14, 2026

Bronchiectasis is a long-term lung disease in which the airways become widened and scarred, trapping mucus and leading to chronic cough, repeated infections and flare-ups. It is far more common than once thought: hundreds of thousands of US adults are estimated to have it, with tens of thousands newly diagnosed each year. Until 2025 there was no approved drug; treatment relied on airway clearance, long-term antibiotics and treating flare-ups. Brensocatib, approved in August 2025, targets neutrophil inflammation, and several similar drugs are in phase 3.

  1. Now

    Nov 2026

    The first approved drugHappened 0.79 flare-up rate ratio

    Brensocatib cut the flare-up rate (rate ratio 0.79 vs placebo) and kept 48.5% flare-free for a year vs 40.3%.

    0.79: rate ratio for flare-ups vs placebo (10 mg).

    A whole drug class emergingHappened 0.41 flare-up rate ratio

    Other DPP-1 and cathepsin C blockers also reduced flare-ups in phase 2.

    0.41: rate ratio for flare-ups vs placebo (40 mg).

    Mucus thinners questionedHappened 0.76 flare-ups per year

    Hypertonic saline (0.76 vs 0.98 flare-ups a year) and carbocisteine did not significantly reduce flare-ups.

    0.76: flare-ups per year with hypertonic saline, vs 0.98 without.

  2. 6 months

    by May 2027

    HSK31858 phase 3 resultsLikely

    Haisco's phase 3 (669 people) finishes November 2026.

  3. 12 months

    by Nov 2027

    AIRTIVITY resultsPossible 0.66 hazard ratio (phase 2)

    Boehringer's BI 1291583 phase 3 (1,755 people) is due June 2027.

    0.66: hazard ratio for first flare-up at 2.5 mg.

    EnsifentrinePossible

    A nebulized COPD drug that opens airways and reduces inflammation is in a 284-person trial due September 2027.

  4. 3 years

    by late 2029

    More anti-inflammatory approachesLong shot

    UCB's galvokimig (300 people, due February 2029) and CSL's inhaled CSL787 (180 people, due May 2029) target inflammation and infection differently.

  5. 5 years

    by late 2031

    Treatment matched to the causeLong shot

    Trials increasingly match treatment to features such as eosinophils, fungal sensitization or Pseudomonas infection.

Happened Likely Possible Long shot

The research paths

Rising

Neutrophil-targeting pills

0.79 flare-up rate ratio
Details and 3 trialsHide
Active

Inhaled and novel anti-inflammatories

Details and 3 trialsHide
Mixed

Mucus and infection

0.76 flare-ups per year
Details and 2 trialsHide

Borrowed from other conditions

From COPD

Ensifentrine

Phase 2

An inhaled PDE3/PDE4 inhibitor approved for COPD in 2024.

From Allergic bronchopulmonary aspergillosis

Itraconazole

Phase 3

An antifungal tested in people sensitized to Aspergillus.

From Primary immune deficiency

Inhaled immunoglobulin (CSL787)

Phase 2

Antibodies from donated plasma, usually given by vein, here inhaled into the airways.

Open to join now

See every recruiting Bronchiectasis trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
HSK31858 vs placeboNeutrophil-targeting pills
Nov 2026
BI 1291583 vs placebo (AIRTIVITY)Neutrophil-targeting pills
Jun 2027
Nebulized ensifentrineInhaled and novel anti-inflammatories
Sep 2027
RSS0343 tabletsNeutrophil-targeting pills
Nov 2027
Dec 2027
GalvokimigInhaled and novel anti-inflammatories
Feb 2029
Nebulized CSL787 (immunoglobulin)Inhaled and novel anti-inflammatories
May 2029

What just happened

Mucus thinners do not significantly cut flare-ups

CLEAR, NEJM.

FDA approves brensocatib, first bronchiectasis drug

ASPEN, NEJM.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See Bronchiectasis trials recruiting now →

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.